id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2035-0007,FDA,FDA-2022-E-2035,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-16T05:00:00Z,2025,1,2025-01-16T05:00:00Z,,2025-01-16T21:21:47Z,,0,0,09000064868c4b41
FDA-2022-E-2035-0006,FDA,FDA-2022-E-2035,Letter from U. S. Patent and Trademark Office,Other,Letter(s),2024-03-06T05:00:00Z,2024,3,2024-03-06T05:00:00Z,,2024-03-06T18:44:06Z,,0,0,09000064863f46e6
FDA-2022-E-2035-0005,FDA,FDA-2022-E-2035,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-01-19T05:00:00Z,2024,1,2024-01-19T05:00:00Z,,2024-01-19T12:58:47Z,,0,0,09000064863a94b8
FDA-2022-E-2035-0004,FDA,FDA-2022-E-2035,Determination of Regulatory Review Period for Purposes of Patent Extension; PONVORY,Notice,Determinations,2023-12-27T05:00:00Z,2023,12,2023-12-27T05:00:00Z,2024-06-25T03:59:59Z,2023-12-27T15:44:15Z,2023-28509,0,0,090000648635c5cc
FDA-2022-E-2035-0003,FDA,FDA-2022-E-2035,Letter to U S Patent and Trademark Office from FDA CDER,Other,Letter(s),2022-09-13T04:00:00Z,2022,9,2022-09-13T04:00:00Z,,2022-09-13T18:52:50Z,,0,0,09000064852f98e3
FDA-2022-E-2035-0002,FDA,FDA-2022-E-2035,Cover Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-08-26T04:00:00Z,2022,8,2022-08-26T04:00:00Z,,2022-08-26T14:55:40Z,,0,0,090000648527613e
FDA-2022-E-2035-0001,FDA,FDA-2022-E-2035,Patent Extension Application from Baker & Hostetler LLP on behalf of Actelion Pharmaceuticals Ltd.,Other,Application,2022-08-26T04:00:00Z,2022,8,2022-08-26T04:00:00Z,,2022-08-26T14:55:16Z,,0,0,090000648527613c